Castration-Resistant Prostate Cancer (CRPC) Live Forum for Urology Residents & Fellows - Washington (2017)

November 27, 2017

The AUA recently released a report on the educational needs of urologists in the area of CRPC. These findings show strong support for the AUA to influence key stakeholders in urology residency programs in order to increase the amount of exposure residents receive in the area of CRPC. Additionally, the findings indicate that the AUA should look into the feasibility of developing stand-alone courses and educational materials specifically targeted to residents that covers the medical management of advanced prostate cancer.

Based on this educational need, AUA is launching a new educational initiative to focus on CRPC Resident & Fellow Training. Based on the documented need for additional education in this area, the AUA has developed multiple educational interventions to improve the urology resident and fellow\'s ability to care for patients with CRPC. The CRPC Resident & Fellow Training initiative is comprised of a variety of unique activities, including a self-assessment, pre-requisite work, a live forum and an online case-study activity. This activity will also provide each participant will access to patient education resources The initiative will offer the live one-day forum five times to reach residents and fellows across the country.

This initiative will provide a foundation of knowledge on CRPC and the ability to apply this knowledge into practice to improve the outcomes of their patients. As residency programs differ in what is offered, we recommend that each participant in this initiative successfully complete all of the activities. If a resident successfully completes all activities, they will receive a Certificate of Participation which they may share with their Residency Program Director.

Target Audience

  • Urology residents
  • Fellows

Learning Objectives

At the completion of this activity, participants will be able to:

Practice Gap #1 (Disease State)

  1. Describe the natural course of advanced prostate cancer from non-metastatic to metastatic hormone sensitive disease, with progression to the development of castration resistant disease.
  2. Explain the implications of castrate resistance on the management of prostate cancer.
  3. Understand the molecular mechanisms and characterization of CRPC.
  4. Describe the role, indications and techniques for imaging of CRPC.

Practice Gap #2 (Guidelines)

  1. Discuss specific recommendations within the AUA Clinical Practice Guidelines.
  2. Construct a patient care plan using the AUA Clinical Practice Guidelines.
  3. Compare and contrast AUA, NCCN, and EAU CRPC Guidelines.
  4. Describe gaps in the knowledge for treatment and sequencing of agents in the management of CRPC.

Practice Gap #3 (Androgen Axis)

  1. Identify recently approved androgen biosynthesis and receptor blockers for treatment of mCRPC.
  2. Contrast the mechanisms of action of recently approved androgen-axis therapeutics for mCRPC.
  3. Appraise the clinical efficacy of recently approved androgen-axis therapeutics for mCRPC.
  4. Organize and order approved therapeutics for use in patients with CRPC.
  5. Anticipate, manage and treat adverse events from therapeutic interventions directed at the androgen-axis used in the treatment of mCRPC.

Practice Gap #4 (Chemotherapy and Immunotherapy and Co-Morbidity)

  1. Identify approved chemotherapeutics for CRPC.
  2. Identify approved immunotherapy for CRPC.
  3. Contrast the mechanisms of action of approved chemotherapy and immune-based therapeutics for mCRPC.
  4. Describe indications and contraindications for recommending chemotherapy and immunotherapy in patients with mCRPC
  5. Appraise the clinical efficacy of approved chemotherapy and immunotherapy for mCRPC.
  6. Identify, assist and treat adverse events from chemo and immune-based therapeutic interventions in the treatment of CRPC.
  7. Identify co-morbid states and recognize their impact on treatment options for mCRPC.

Practice Gap #5 (Bone Health and Radionuclide Therapy)

  1. Integrate advances in bone health management into patient-specific care plans.
  2. Proactively prescribe and manage side effects of therapeutics used for reducing skeletal related events in mCRPC.
  3. Identify patients and prescribe radionuclide therapy in appropriate patients with symptomatic mCRPC.

Practice Gaps #6 (Pain Management and Palliative Care)

  1. Assess and manage pain in patients with CRPC.
  2. Counsel patients on medication adherence.
  3. Support patients as they transition to palliative care at the end of the patients' life.
Course summary
Available credit: 
  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Non-Physician Participation
Course opens: 
09/04/2017
Course expires: 
11/27/2020
Event starts: 
11/27/2017 - 7:00am EST
Event ends: 
11/27/2017 - 5:00pm EST
Add to calendar: 
Rating: 
0

7:00 – 8:00 a.m.                    Registration & Continental Breakfast with the Experts

 

8:00 – 8:15 a.m.                    Welcome

                                               Leonard G. Gomella, MD, FACS

                                               Michael S. Cookson, MD, MHHC

                                               David F. Jarrard, MD

 

8:15 – 8:30 a.m.                    Pre-Test

                                               Michael S. Cookson, MD, MHHC

                                               David F. Jarrard, MD

 

Session I

8:30 – 8:55 a.m.                     Initial Management of Advanced Prostate Cancer and Characterization of Castrate-Resistant Disease
                                               Todd M. Morgan, MD

                                               

8:55 – 9:10 a.m.                     Imaging of Advanced Prostate Cancer
                                               Todd M. Morgan, MD

                                               

9:10 – 9:40 a.m.                    Review of Guidelines
                                               Michael S. Cookson, MD, MHHC

                                               

9:40 – 9:45 a.m.                    Post-Test

                                               Michael S. Cookson, MD, MHHC
                                               David F. Jarrard, MD

 

9:45 – 10:00 a.m.                  Break

 

 

Session II

10:00 – 10:30 a.m.               Secondary Hormone Manipulation and Mechanisms of Progression to Castration- Resistant Disease

                                             David F. Jarrard, MD

                                               

10:30 – 11:10 a.m.               Manipulating the Androgen Axis:  Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents

                                             Leonard G. Gomella, MD, FACS

                                               

11:10 – 11:45 a.m.               Roundtable Discussion of Index Patients
                                             David F. Jarrard, MD & Leonard G. Gomella, MD, FACS

                                               

11:45 – 11:50 a.m.               Post-Test
                                             David F. Jarrard, MD

 

11:50 a.m. – 1:15 p.m.         "Elevate Care in Advanced Prostate Cancer"
                                             A Non-CME Lunch Symposium supported by Astellas Pharma US, Inc. and Pfizer Oncology

 

Session III

1:15 – 1:45 p.m.                   Role of Chemotherapy and Performance Status
                                             Robert Dreicer, MD

                                               

1:45 – 2:05 p.m.                   Immunotherapy Approaches to CRPC

                                             Kelly L. Stratton, MD

                                               

2:05 – 2:40 p.m.                   Roundtable Discussion of Index Patients
                                             Kelly L. Stratton, MD & Robert Dreicer, MD

                                               

2:40 – 2:45 p.m.                   Post-Test

                                             Michael S. Cookson, MD, MHHC
                                             David F. Jarrard, MD

 

2:45 – 3:00 p.m.                   Break

Session IV

3:00 – 3:25 p.m.                   Radiopharmaceuticals in Advanced Prostate Cancer and Bone Health

                                             Stephen A. Boorjian, MD

 

3:25 – 3:50 p.m.                   Pain Management and Palliative Care
                                             Edouard J. Trabulsi, MD, FACS

 

3:50 – 4:15 p.m.                   Multidisciplinary Care Models
                                             Edouard J. Trabulsi, MD, FACS

 

4:15 – 4:40 p.m.                   Roundtable Discussion of Index Patients
                                             Stephen A. Boorjian, MD & Edouard J. Trabulsi, MD, FACS

                                               

4:40 – 4:45 p.m.                   Post-Test

                                             Michael S. Cookson, MD, MHHC
                                             David F. Jarrard, MD

 

4:45 – 5:00 p.m.                   Closing Remarks

                                             Michael S. Cookson, MD, MHHC
                                             David F. Jarrard, MD

 

Renaissance Washington DC Hotel
Washington, DC
United States

Name

Company

Role

Financial

Stephen A. Boorjian, MD

SUO-CTC Organized Clinical Trial Sponsored by FKD

Scientific Study or Trial

No

Michael Cookson, MD, MMHC

Astellas

Consultant or Advisor

Yes

TesoRx Pharma LLC

Consultant or Advisor

Yes

Janssen Biotech, Inc.

Consultant or Advisor

Yes

Photocure

Meeting Participant or Lecturer, Scientific Study or Trial

Yes

Myovant Sciences

Consultant or Advisor

Yes

Genomic Health

Consultant or Advisor

Yes

MDxHealth

Consultant or Advisor

Yes

Pacific Edge Diagnostics USA

Consultant or Advisor

Yes

Matthew Cooperberg, MD

Dendreon

Consultant or Advisor

Yes

Myriad Genetics

Consultant or Advisor

Yes

Astellas

Consultant or Advisor

Yes

Robert Dreicer, MD

Asana

Consultant or Advisor

Yes

Genentech

Consultant or Advisor

Yes

Medivation

Consultant or Advisor

Yes

Roche

Consultant or Advisor

Yes

BMS

Consultant or Advisor

Yes

AstraZeneca

Consultant or Advisor

Yes

David F. Jarrard, MD

Gregor Diagnostics

Consultant or Advisor

No

Daniel W. Lin, MD

NIH/NCI

Scientific Study or Trial

Yes

Todd Morgan, MD

Visible Health, Inc

Leadership Position, Owner, Product Development

Yes

Myriad Genetics

Scientific Study or Trial

Yes

MDx Health

Scientific Study or Trial

Yes

GenomeDx

Scientific Study or Trial

Yes

Kelly Stratton, MD

Ebix

Other

Yes

Bayer Corporation

Consultant or Advisor

Yes

Oakstone

Other

Yes

Edouard John Trabulsi, MD

GenomeDx

Consultant or Advisor

Yes

Evan Y. Yu, MD

Agensys

Consultant or Advisor, Scientific Study or Trial

Yes

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Non-Physician Participation
Please login or register to take this course.